JPH0930954A - Beautifying and whitening dermal preparation for external use - Google Patents
Beautifying and whitening dermal preparation for external useInfo
- Publication number
- JPH0930954A JPH0930954A JP8084750A JP8475096A JPH0930954A JP H0930954 A JPH0930954 A JP H0930954A JP 8084750 A JP8084750 A JP 8084750A JP 8475096 A JP8475096 A JP 8475096A JP H0930954 A JPH0930954 A JP H0930954A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- whitening
- beautifying
- phase
- iris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000002500 effect on skin Effects 0.000 title abstract 5
- 241001113425 Iridaceae Species 0.000 claims abstract description 15
- IAJIIJBMBCZPSW-RKDXNWHRSA-N (+)-Eleutherin Natural products O=C1C=2C(OC)=CC=CC=2C(=O)C2=C1[C@@H](C)O[C@H](C)C2 IAJIIJBMBCZPSW-RKDXNWHRSA-N 0.000 claims abstract description 8
- IAJIIJBMBCZPSW-DTWKUNHWSA-N Eleutherin Chemical compound O=C1C=2C(OC)=CC=CC=2C(=O)C2=C1[C@@H](C)O[C@@H](C)C2 IAJIIJBMBCZPSW-DTWKUNHWSA-N 0.000 claims abstract description 8
- IAJIIJBMBCZPSW-UHFFFAOYSA-N isoeleutherine Natural products O=C1C=2C(OC)=CC=CC=2C(=O)C2=C1C(C)OC(C)C2 IAJIIJBMBCZPSW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000419 plant extract Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 abstract description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 21
- 241000196324 Embryophyta Species 0.000 abstract description 15
- 238000010438 heat treatment Methods 0.000 abstract description 14
- 102000003425 Tyrosinase Human genes 0.000 abstract description 12
- 108060008724 Tyrosinase Proteins 0.000 abstract description 12
- 235000015265 Iris pallida Nutrition 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 239000006071 cream Substances 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 208000003351 Melanosis Diseases 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 206010008570 Chloasma Diseases 0.000 abstract description 3
- 206010014970 Ephelides Diseases 0.000 abstract description 3
- 206010042496 Sunburn Diseases 0.000 abstract description 3
- 150000001298 alcohols Chemical class 0.000 abstract description 3
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 3
- 230000019612 pigmentation Effects 0.000 abstract description 3
- 239000004094 surface-active agent Substances 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 238000010992 reflux Methods 0.000 abstract description 2
- 239000002562 thickening agent Substances 0.000 abstract description 2
- 240000000015 Iris germanica Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000003287 bathing Methods 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 239000000706 filtrate Substances 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 230000003061 melanogenesis Effects 0.000 abstract 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 52
- 239000000203 mixture Substances 0.000 description 38
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 33
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 26
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 19
- -1 methanol and ethanol Chemical class 0.000 description 19
- 239000008346 aqueous phase Substances 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 12
- 239000002304 perfume Substances 0.000 description 11
- 240000004101 Iris pallida Species 0.000 description 10
- 238000004945 emulsification Methods 0.000 description 10
- 240000007327 Eleutherine bulbosa Species 0.000 description 9
- 235000015164 Iris germanica var. florentina Nutrition 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 9
- 239000000469 ethanolic extract Substances 0.000 description 9
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 9
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 9
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 9
- 244000023249 iris florentino Species 0.000 description 9
- 230000008099 melanin synthesis Effects 0.000 description 9
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 229940057995 liquid paraffin Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000401 methanolic extract Substances 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 229940032094 squalane Drugs 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 235000011118 potassium hydroxide Nutrition 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 229910021538 borax Inorganic materials 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 239000004328 sodium tetraborate Substances 0.000 description 4
- 235000010339 sodium tetraborate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical group 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 125000005474 octanoate group Chemical group 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CCWPSKZBVMNDLT-UHFFFAOYSA-N (2-hydroxy-4-methoxyphenyl)-phenylmethanone;sodium Chemical compound [Na].OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 CCWPSKZBVMNDLT-UHFFFAOYSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000128206 Pyracantha coccinea Species 0.000 description 1
- 235000003105 Pyracantha coccinea Nutrition 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明はアヤメ科(Iridacea
e)の植物抽出物を配合する事により、メラニンの生成
を抑制し、日焼け後の色素沈着・しみ・そばかす・肝斑
等の予防および改善に有効な美白用皮膚外用剤に関す
る。TECHNICAL FIELD The present invention relates to the family Iridacea.
The present invention relates to an external preparation for whitening skin, which is effective in preventing melanin production and preventing and improving pigmentation, spots, freckles, chloasma, etc. after sunburn by incorporating the plant extract of e).
【0002】[0002]
【従来の技術】皮膚のしみなどの発生機序については一
部不明な点もあるが、一般には、ホルモンの異常や日光
からの紫外線の刺激が原因となってメラニン色素が形成
され、これが皮膚内に異常沈着するものと考えられてい
る。皮膚の着色の原因となるこのメラニン色素は、表皮
と真皮との間にあるメラニン細胞(メラノサイト)内の
メラニン生成顆粒(メラノソーム)において生産され、
生成したメラニンは、浸透作用により隣接細胞へ拡散す
る。このメラノサイト内における生化学反応は、次のよ
うなものと推定されている。すなわち、必須アミノ酸で
あるチロシンが酵素チロシナーゼの作用によりドーパキ
ノンとなり、これが酵素的または非酵素的酸化作用によ
り赤色色素および無色色素を経て黒色のメラニンへ変化
する過程がメラニン色素の生成過程である。従って、反
応の第1段階であるチロシナーゼの作用を抑制すること
が、メラニン生成の抑制に重要である。2. Description of the Related Art Although there are some unclear points about the mechanism of the occurrence of skin spots and the like, melanin pigments are generally formed due to hormonal abnormalities and stimulation of ultraviolet rays from sunlight. It is believed to be abnormally deposited within. This melanin pigment, which causes skin coloring, is produced in melanin-producing granules (melanosomes) in melanocytes (melanocytes) between the epidermis and dermis,
The generated melanin diffuses into adjacent cells by the osmotic effect. The biochemical reaction in this melanocyte is presumed to be as follows. That is, tyrosine, which is an essential amino acid, is converted into dopaquinone by the action of the enzyme tyrosinase, and the process in which it is converted to black melanin via a red pigment and a colorless pigment by an enzymatic or non-enzymatic oxidative action is a melanin pigment production process. Therefore, suppressing the action of tyrosinase, which is the first step of the reaction, is important for suppressing melanin production.
【0003】[0003]
【発明が解決しようとする課題】しかしチロシナーゼ作
用を抑制する化合物はハイドロキノンを除いてはその効
果の発現がきわめて緩慢であるため、皮膚色素沈着の改
善効果が十分でない。一方、ハイドロキノンは効果は一
応認められているが、感作性があるため、一般には使用
が制限されている。そこでその安全性を向上させるた
め、高級脂肪酸のモノエステルやアルキルモノエーテル
などにする試み(特開昭58−154507号公報)が
なされているが、エステル類は体内の加水分解酵素によ
って分解されるため必ずしも安全とはいいがたく、また
エーテル類も安全性の面で充分に満足するものが得られ
ていない。However, compounds that suppress the tyrosinase action, except for hydroquinone, have very slow onset of their effects, so that the effect of improving skin pigmentation is not sufficient. On the other hand, although hydroquinone is recognized as having an effect, its use is generally restricted because of its sensitizing properties. Therefore, in order to improve its safety, attempts have been made to use higher fatty acid monoesters or alkyl monoethers (JP-A-58-154507), but the esters are decomposed by a hydrolase in the body. Therefore, it is not always safe, and ethers have not been sufficiently satisfactory in terms of safety.
【0004】[0004]
【課題を解決するための手段】そこで本発明者らはこれ
らの問題を解決するものとして広く種々の物質について
メラニン生成抑制効果を調べた結果、アヤメ科(Iridac
eae)の植物抽出物がメラニン生成抑制作用およびチロ
シナーゼ阻害作用を有していることを見い出し、本発明
を完成するに至った。アヤメ科(Iridaceae)の植物抽
出物のメラニン生成抑制作用等に関する報告はこれまで
になく、美白剤への応用も全く知られていない。本発明
者らは上記知見に基づいて本発明を完成するに至った。The inventors of the present invention investigated the melanin production inhibitory effect of various substances as a solution to these problems, and found that the iris family (Iridac)
It was found that the plant extract of eae) has a melanin production inhibitory action and a tyrosinase inhibitory action, and completed the present invention. There has been no report on the melanin production inhibitory action of a plant extract of Iridaceae, and its application to a whitening agent has not been known at all. The present inventors have completed the present invention based on the above findings.
【0005】すなわち本発明は、アヤメ科(Iridacea
e)の植物抽出物を配合することを特徴とする美白用皮
膚外用剤である。That is, the present invention relates to the family Iridacea.
An external preparation for whitening skin, characterized by containing the plant extract of e).
【0006】以下、本発明の構成について詳述する。本
発明に用いられるアヤメ科(Iridaceae)の植物は、エ
レウセリン属(Eleutherin)の植物またはイリス属(Ir
is)の植物であることが好ましい。エレウセリン属(El
eutherin)の植物としては、ホンコン(Eleutherin ame
ricana Mevr.et Heyne)、Eleutherin bulbosa(Miller)
Urb.、Eleutherin subaphylla が挙げられる。また、イ
リス属(Iris)の植物としては、ムラサキイリス(Iris
pallida)、シロバナイリス(Iris florentina)が挙
げられる。The structure of the present invention will be described in detail below. The plant of the iris family (Iridaceae) used in the present invention is a plant of the genus Eleutherin or the genus Iris.
is) plants are preferred. Eleutherin (El
eutherin) plants include Hong Kong (Eleutherin ame
ricana Mevr.et Heyne), Eleutherin bulbosa (Miller)
Urb. And Eleutherin subaphylla. In addition, as a plant of the genus (Iris),
pallida) and white iris (Iris florentina).
【0007】本発明に用いられるアヤメ科(Iridacea
e)の植物は、広く世界中に分布している植物で、特に
乾性草原、牧草などに生える植物である。本発明に用い
られる植物抽出物は、これらの植物の葉と茎または果実
等、全草を抽出溶媒と共に浸漬または加熱還流した後、
濾過し、濃縮して得られる。本発明に用いられる抽出溶
媒は、通常抽出に用いられる溶媒であれば何でもよく、
特にメタノール、エタノール等のアルコール類、含水ア
ルコール類、アセトン、酢酸エチルエステル等の有機溶
媒を単独あるいは組み合わせて用いることができる。Iridacea used in the present invention
The plant e) is a plant that is widely distributed all over the world, and is a plant that grows in the dry grass and grass. The plant extract used in the present invention, such as leaves and stems or fruits of these plants, after soaking or heating and refluxing the whole plant with an extraction solvent,
Obtained by filtration and concentration. The extraction solvent used in the present invention may be any solvent used in ordinary extraction,
In particular, alcohols such as methanol and ethanol, hydroalcohols, organic solvents such as acetone and ethyl acetate can be used alone or in combination.
【0008】本発明におけるアヤメ科(Iridaceae)の
植物抽出物の配合量は、外用剤全量中、乾燥物として
0.005〜20.0重量%、好ましくは0.01〜1
0.0重量%である。0.005重量%未満であると、
本発明でいう効果が十分に発揮されず、20.0重量%
を超えると製剤化が難しいので好ましくない。また、1
0.0重量%以上配合してもさほど大きな効果の向上は
みられない。The amount of the plant extract of the family Iridaceae used in the present invention is 0.005 to 20.0% by weight, preferably 0.01 to 1% by weight, based on the total weight of the external preparation.
0.0% by weight. When it is less than 0.005% by weight,
The effect of the present invention is not sufficiently exerted and 20.0% by weight
If it exceeds, it is not preferable because formulation is difficult. Also, 1
Even if it is added in an amount of 0.0% by weight or more, the effect is not significantly improved.
【0009】また、本発明の美白用皮膚外用剤には、上
記必須成分以外に、通常化粧品や医薬品等の皮膚外用剤
に用いられる成分、例えば、その他の美白剤、保湿剤、
酸化防止剤、油性成分、紫外線吸収剤、界面活性剤、増
粘剤、アルコール類、粉末成分、色材、水性成分、水、
各種皮膚栄養剤等を必要に応じて適宜配合することがで
きる。In addition to the above-mentioned essential components, the external whitening agent for skin whitening of the present invention also contains components that are usually used in external skin external agents such as cosmetics and pharmaceuticals, such as other whitening agents and moisturizers.
Antioxidants, oily components, UV absorbers, surfactants, thickeners, alcohols, powder components, coloring materials, aqueous components, water,
Various skin nutrients and the like can be appropriately compounded as needed.
【0010】その他、エデト酸二ナトリウム、エデト酸
三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリ
ウム、メタリン酸ナトリウム、グルコン酸等の金属封鎖
剤、カフェイン、タンニン、ベラパミル、トラネキサム
酸およびその誘導体、甘草抽出物、グラブリジン、火棘
の果実の熱水抽出物、各種生薬、酢酸トコフェロール、
グリチルリチン酸およびその誘導体またはその塩等の薬
剤、ビタミンC、アスコルビン酸リン酸マグネシウム、
アスコルビン酸グルコシド、アルブチン、コウジ酸等の
他の美白剤、グルコース、フルクトース、マンノース、
ショ糖、トレハロース等の糖類なども適宜配合すること
ができる。In addition, sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice extraction Substance, glabridin, hot water extract of fruits of fire thorns, various crude drugs, tocopherol acetate,
Drugs such as glycyrrhizic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate,
Other whitening agents such as ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, mannose,
Sugars such as sucrose and trehalose can also be appropriately blended.
【0011】本発明の美白用皮膚外用剤とは、例えば軟
膏、クリーム、乳液、ローション、パック、浴用剤等、
従来皮膚外用剤に用いるものであればいずれでもよく、
剤型は特に問わない。The external preparation for whitening skin of the present invention includes, for example, ointments, creams, emulsions, lotions, packs, bath agents and the like.
Any conventional skin external preparation may be used,
The dosage form is not particularly limited.
【0012】[0012]
【実施例】次に実施例によって本発明をさらに詳細に説
明する。尚、本発明はこれにより限定されるものではな
い。配合量は重量%である。実施例に先立ち、本発明の
植物抽出物のメラニン抑制効果、チロシナーゼ活性阻害
効果および美白効果に関する試験方法とその結果につい
て説明する。Next, the present invention will be described in more detail by way of examples. Note that the present invention is not limited by this. The blending amount is% by weight. Prior to Examples, test methods and results of the melanin suppressing effect, tyrosinase activity inhibiting effect and whitening effect of the plant extract of the present invention will be described.
【0013】試験方法およびその結果 1.試料の調製 アヤメ科の植物の茎および枝部分50gを、室温で1週
間エタノールに浸漬し、抽出液を濃縮し、エタノール抽
出物5.2gを得た。この抽出物をDMSOに1%溶か
し、この溶液を希釈して濃度を調整し、これを用いて以
下の実験を行った。 Test Method and Results 1. Preparation of Sample 50 g of stem and branch of Iridaceae plant was immersed in ethanol at room temperature for 1 week, and the extract was concentrated to obtain 5.2 g of ethanol extract. This extract was dissolved in DMSO at 1%, the concentration was adjusted by diluting this solution, and the following experiment was performed using this.
【0014】2.細胞培養法 マウス由来のB16メラノーマ培養細胞を使用した。1
0%FBSおよびテオフィリン(0.09mg/ml)
を含むイーグルMEM培地中でCO2インキュベーター
(95%空気,5%二酸化炭素)内、37℃の条件下で
培養した。培養24時間後に試料溶液を終濃度(抽出乾
燥物換算濃度)で10-2〜10-5重量%になるように添
加し、さらに3日間培養を続け、以下の方法でメラニン
生成量の視感判定およびチロシナーゼ活性阻害効果を測
定した。2. Cell culture method B16 melanoma cultured cells derived from mice were used. 1
0% FBS and theophylline (0.09 mg / ml)
The cells were cultured in an Eagle MEM medium containing C. in a CO 2 incubator (95% air, 5% carbon dioxide) at 37 ° C. After 24 hours of culturing, the sample solution was added so as to have a final concentration (concentration of extracted dry matter) of 10 -2 to 10 -5 % by weight, culturing was continued for another 3 days, and the melanin production amount was visually sensed by the following method. The determination and the tyrosinase activity inhibitory effect were measured.
【0015】3.メラニン量の視感測定 ウエルのプレートの蓋の上に拡散板を置き、倒立顕微鏡
で細胞内のメラニン量を観察し、アヤメ科の植物抽出物
を添加していない試料(基準)の場合と比較した。その
結果を表1に表示した。また、参考例として、すでにメ
ラニン生成抑制作用のあることが知られているケイガイ
(シソ科オドリコソウ亜科)抽出物についても上記と同
様の試験を行った。その結果を併せて表1に示す。3. Visual measurement of melanin amount Place a diffusion plate on the lid of the well plate, observe the intracellular melanin amount with an inverted microscope, and compare with the sample (standard) to which Iridaceae plant extract is not added did. The results are shown in Table 1. In addition, as a reference example, the same test as above was carried out on an extract of Kaigai (Lamiaceae, Odorikosou Subfamily), which is already known to have an action of suppressing melanin production. Table 1 also shows the results.
【0016】<判定基準> ○:白(メラニン量) △:やや白(メラニン量) ×:基準(メラニン量)<Criteria> ○: White (amount of melanin) Δ: Slightly white (amount of melanin) ×: Reference (amount of melanin)
【0017】4.チロシナーゼ活性の測定 測定前にウエル中の培地は除去し、PBS100μlで
2回洗う。各ウエルに45μlの1%トライトン−X
(ローム・アンド・ハース社製商品名、界面活性剤)を
含むPBSを加える。1分間プレートを振動させ、よく
細胞膜を破壊し、マイクロプレートリーダーで475n
mの吸光度を測定してこれを0分時の吸光度とした。そ
の後、すばやく5μlの10mMのL−DOPA溶液を
加えて、37℃のインキュベーターに移し、60分間反
応させた。1分間プレートを振動させ、60分時の吸光
度(475nm)を測定した。アヤメ科の植物抽出物を
添加していない試料(コントロール)の場合の0分時と
60分時の吸光度差に対するアヤメ科の植物抽出物添加
試料の前記吸光度差の減少分をチロシナーゼ活性阻害率
(%)とした。その結果を表1に示す。4. Measurement of tyrosinase activity Before measurement, the medium in the wells is removed and washed twice with 100 μl of PBS. 45 μl of 1% Triton-X in each well
(Rohm and Haas product name, surfactant) containing PBS is added. Shake the plate for 1 minute, break the cell membrane well, and use a microplate reader for 475n.
The absorbance at m was measured, and this was taken as the absorbance at 0 minutes. Then, 5 μl of 10 mM L-DOPA solution was quickly added, and the mixture was transferred to an incubator at 37 ° C. and reacted for 60 minutes. The plate was shaken for 1 minute, and the absorbance (475 nm) at 60 minutes was measured. The tyrosinase activity inhibition rate was calculated based on the decrease in the absorbance difference of the sample containing Iridaceae plant extract relative to the difference in absorbance at 0 minutes and 60 minutes in the case of the sample (control) to which the plant extract of Iridaceae was not added ( %). Table 1 shows the results.
【0018】また、参考例として、すでにチロシナーゼ
活性阻害作用のあることが知られているケイガイのエタ
ノール抽出物についても上記と同様の試験を行った。そ
の結果を併せて表1に示す。なお、表中、−は、コント
ロールに比べて、危険率5%以内で有意な差が認められ
なかったことを意味する。Further, as a reference example, the same test as above was carried out on an ethanol extract of mussel, which is already known to have a tyrosinase activity inhibitory action. Table 1 also shows the results. In addition,-in a table | surface means that the significant difference was not recognized within 5% of the risk ratio compared with the control.
【0019】[0019]
【表1】 ─────────────────────────────────── 試験 メラニン生成視感評価 チロシナーゼ活性阻害率(%) ──────── ──────────────────────── 濃度(重量%) 10-5 10-4 10-3 10-2 10-5 10-4 10-3 10-2 ─────────────────────────────────── ホンコン抽出物 × × × ○ − − 35 94 E.bulbosa 抽出物 × × × ○ − − 33 97 E.subaphylla 抽出物 × × × ○ − − 36 95 Iris pallida 抽出物 × × ○ ◎ − 9 31 62 Iris florentina 抽出物 × × △ ○ − 5 24 52 ケイガイ抽出物 × × × × − − − 55 ───────────────────────────────────[Table 1] ─────────────────────────────────── Test Melanin production Visual evaluation Tyrosinase activity inhibition rate ( %) ──────── ──────────────────────── concentration (wt%) 10 -5 10 -4 10 -3 10 - 2 10 -5 10 -4 10 -3 10 -2 ─────────────────────────────────── Hong Kong extraction Extract × × × ○ − − 35 94 E. bulbosa extract × × × ○ − − 33 97 E. subaphylla extract × × × ○ − − 36 95 Iris pallida extract × × ○ ◎ − 9 31 62 Iris florentina extract Material × × △ ○ − 5 24 52 Clam shell extract × × × × − − − 55 ─────────────────────────────── ─────
【0020】5.美白効果試験 [試験方法]夏期の太陽光に4時間(1日2時間で2日
間)晒された被験者136名の上腕内側部皮膚を対象と
して太陽光に晒された日の5日後より各試料を朝夕1回
ずつ4週間塗布した。パネルを一群8名に分けて、17
群とし下記に示す処方で試験を行った。 (アルコール相) 95%エチルアルコール 55.0 重量% ポリオキシエチレン(25モル)硬化ヒマシ油エーテル 2.0 酸化防止剤・防腐剤 適量 香料 適量 薬剤(表2記載) (水相) グリセリン 5.0 ヘキサメタリン酸ナトリウム 適量 イオン交換水 残余 <製法>水相、アルコール相をそれぞれ調製し、その後
両者を混合して可溶化する。[5] Whitening test [Test method] 136 subjects exposed to sunlight in summer for 4 hours (2 hours per day for 2 days) each sample from 5 days after the day of sun exposure to the skin of the upper arm inner skin Was applied once each morning and evening for 4 weeks. The panel is divided into 8 groups and 17
The group was tested with the formulation shown below. (Alcohol phase) 95% Ethyl alcohol 55.0% by weight Polyoxyethylene (25 moles) hydrogenated castor oil ether 2.0 Antioxidant / preservative proper amount Fragrance proper amount drug (listed in Table 2) (water phase) glycerin 5.0 Sodium hexametaphosphate Suitable amount Ion-exchanged water Residue <Production method> An aqueous phase and an alcohol phase are prepared, respectively, and then both are mixed and solubilized.
【0021】[評価方法]使用後の淡色化効果を下記の
判定基準に基づいて判定した。 <判定基準> ◎:被験者のうち著効および有効の示す割合が80%以
上の場合 ○:被験者のうち著効および有効の示す割合が50%〜
80%未満の場合 △:被験者のうち著効および有効の示す割合が30%〜
50%未満の場合 ×:被験者のうち著効および有効の示す割合が30%未
満の場合[Evaluation Method] The lightening effect after use was judged based on the following judgment criteria. <Judgment criteria> :: When the ratio showing significant effect and effectiveness among the subjects is 80% or more 割 合: The ratio showing significant effect and effectiveness among the subjects is 50% or more
Less than 80% △: The proportion of the test subjects showing excellent and effective is 30% or more
When less than 50% x: When the ratio of markedly effective or effective among the subjects is less than 30%
【0022】上記試験法記載の配合組成からなる試料を
調製し、表2記載の薬剤を用いて美白効果を比較した。
結果は表2に示す。Samples having the blending composition described in the above test method were prepared and the whitening effect was compared using the agents shown in Table 2.
The results are shown in Table 2.
【0023】[0023]
【表2】 ────────────────────────── 薬 剤 配合量(重量%) 効 果 ────────────────────────── 無添加 − × ハイドロキノン 1.0 △ ホンコン抽出物 0.1 ○ ホンコン抽出物 1.0 ○ ホンコン抽出物 10.0 ◎ E.bulbosa 抽出物 0.1 ○ E.bulbosa 抽出物 1.0 ○ E.bulbosa 抽出物 10.0 ◎ E.subaphylla 抽出物 0.1 ○ E.subaphylla 抽出物 1.0 ○ E.subaphylla 抽出物 10.0 ◎ Iris pallida 抽出物 0.1 ○ Iris pallida 抽出物 1.0 ○ Iris pallida 抽出物 1.0 ◎ Iris florentina 抽出物 0.1 ○ Iris florentina 抽出物 1.0 ○ Iris florentina 抽出物 1.0 ◎ ──────────────────────────[Table 2] ────────────────────────── Drug compounding amount (% by weight) Effect ────────── ──────────────── Additive- × Hydroquinone 1.0 △ Hong Kong extract 0.1 ○ Hong Kong extract 1.0 ○ Hong Kong extract 10.0 ◎ E. bulbosa extract Material 0.1 ○ E.bulbosa extract 1.0 ○ E.bulbosa extract 10.0 ◎ E.subaphylla extract 0.1 ○ E.subaphylla extract 1.0 ○ E.subaphylla extract 10.0 ◎ Iris pallida extract 0.1 ○ Iris pallida extract 1.0 ○ Iris pallida extract 1.0 ◎ Iris florentina extract 0.1 ○ Iris florentina extract 1.0 ○ Iris florentina extract 1.0 ◎ ── ────────────────────────
【0024】なお、表2のホンコン抽出物、E.bulbosa
抽出物、E.subaphylla 抽出物、Iris pallida 抽出物お
よびIris florentina 抽出物は、これらの植物の全草を
エタノール中で加熱還元した後、濾過、濃縮乾燥して得
たものである。The Hong Kong extract of Table 2 and E. bulbosa
The extract, E. subaphylla extract, Iris pallida extract, and Iris florentina extract were obtained by heating and reducing whole plants of these plants in ethanol, filtering, and concentrating and drying.
【0025】表2より明らかな様に、太陽光に晒された
後の効果はアヤメ科の植物抽出物を添加した方が過剰の
メラニン色素の沈着を防ぎ、色黒になることを予防する
ことが認められた。As is clear from Table 2, the effect after exposure to sunlight is to prevent excessive melanin pigment deposition and prevent darkening by adding a plant extract of Iridaceae. Was recognized.
【0026】実施例1 クリーム(処方) ステアリン酸 5.0 重量% ステアリルアルコール 4.0 イソプロピルミリステート 18.0 グリセリンモノステアリン酸エステル 3.0 プロピレングリコール 10.0 ホンコンメタノール抽出物 0.01 苛性カリ 0.2 亜硫酸水素ナトリウム 0.01 防腐剤 適量 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールとホンコ
ンメタノール抽出物と苛性カリを加え溶解し、加熱して
70℃に保つ(水相)。他の成分を混合し加熱融解して
70℃に保つ(油相)。水相に油相を徐々に加え、全部
加え終わってからしばらくその温度に保ち反応を起こさ
せる。その後、ホモミキサーで均一に乳化し、よくかき
まぜながら30℃まで冷却する。Example 1 Cream (formulation) Stearic acid 5.0% by weight Stearyl alcohol 4.0 Isopropyl myristate 18.0 Glycerin monostearate 3.0 Propylene glycol 10.0 Hong Kong methanol extract 0.01 Caustic potash 0 .2 Sodium bisulfite 0.01 Preservative proper amount Perfume proper amount Ion-exchanged water Residue (production method) Dissolve propylene glycol, Hong Kong methanol extract and caustic potash in ion-exchanged water, heat and keep at 70 ° C (water phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is gradually added to the water phase, and after the addition is completed, the temperature is maintained for a while to cause a reaction. Then, it is uniformly emulsified with a homomixer and cooled to 30 ° C. with thorough stirring.
【0027】実施例2 クリーム (処方) ステアリン酸 2.0 重量% ステアリルアルコール 7.0 水添ラノリン 2.0 スクワラン 5.0 2−オクチルドデシルアルコール 6.0 ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0 グリセリンモノステアリン酸エステル 2.0 プロピレングリコール 5.0 E.bulbosa エタノール抽出物 0.05 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し加熱
融解して70℃に保つ(油相)。水相に油相を加え予備
乳化を行い、ホモミキサーで均一に乳化した後、よくか
きまぜながら30℃まで冷却する。Example 2 Cream (formulation) Stearic acid 2.0% by weight Stearyl alcohol 7.0 Hydrogenated lanolin 2.0 Squalane 5.0 2-Octyldodecyl alcohol 6.0 Polyoxyethylene (25 mol) cetyl alcohol ether 3.0 Glycerin monostearate 2.0 Propylene glycol 5.0 E. bulbosa ethanol extract 0.05 Sodium hydrogen sulfite 0.03 Ethylparaben 0.3 Perfume suitable amount Ion-exchanged water Residue (production method) Propylene in ion-exchanged water Add glycol,
Heat and maintain at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the aqueous phase to carry out preliminary emulsification, and the mixture is uniformly emulsified with a homomixer and then cooled to 30 ° C. with thorough stirring.
【0028】実施例3 クリーム (処方) 固形パラフィン 5.0 重量% ミツロウ 10.0 ワセリン 15.0 流動パラフィン 41.0 グリセリンモノステアリン酸エステル 2.0 ポリオキシエチレン(20モル)ソルビタンモノラウリン酸エステル 2.0 石けん粉末 0.1 硼砂 0.2 E.subaphylla アセトン抽出物 0.05 ホンコンエタノール抽出物 0.05 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水に石けん粉末と硼砂を加え、加熱
溶解して70℃に保つ(水相)。他の成分を混合し加熱
融解して70℃に保つ(油相)。水相に油相をかきまぜ
ながら徐々に加え反応を行う。反応終了後、ホモミキサ
ーで均一に乳化し、乳化後よくかきまぜながら30℃ま
で冷却する。Example 3 Cream (Formulation) Solid paraffin 5.0% by weight Beeswax 10.0 Vaseline 15.0 Liquid paraffin 41.0 Glycerin monostearate 2.0 Polyoxyethylene (20 mol) sorbitan monolaurate 2 .0 soap powder 0.1 borax 0.2 E. subaphylla acetone extract 0.05 Hong Kong ethanol extract 0.05 sodium bisulfite 0.03 ethylparaben 0.3 perfume proper amount ion-exchanged water residual (production method) ion-exchanged water Soap powder and borax are added to the mixture, heated and melted and kept at 70 ° C (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is gradually added to the aqueous phase while stirring to carry out the reaction. After the reaction is completed, the mixture is uniformly emulsified with a homomixer, and after emulsification, the mixture is cooled to 30 ° C. with thorough stirring.
【0029】実施例4 乳液 (処方) ステアリン酸 2.5 重量% セチルアルコール 1.5 ワセリン 5.0 流動パラフィン 10.0 ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0 ポリエチレングリコール1500 3.0 トリエタノールアミン 1.0 カルボキシビニルポリマー 0.05 (商品名:カーボポール941,B.F.Goodrich Chemical company) E.bulbosa 酢酸エチルエステル抽出物 0.01 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)少量のイオン交換水にカルボキシビニルポリマ
ーを溶解する(A相)。残りのイオン交換水にポリエチ
レングリコール1500とトリエタノールアミンを加
え、加熱溶解して70℃に保つ(水相)。他の成分を混
合し加熱融解して70℃に保つ(油相)。水相に油相を
加え予備乳化を行い、A相を加えホモミキサーで均一乳
化し、乳化後よくかきまぜながら30℃まで冷却する。Example 4 Emulsion (formulation) Stearic acid 2.5 wt% Cetyl alcohol 1.5 Vaseline 5.0 Liquid paraffin 10.0 Polyoxyethylene (10 mol) monooleate 2.0 Polyethylene glycol 1500 3. 0 triethanolamine 1.0 carboxyvinyl polymer 0.05 (trade name: Carbopol 941, BFGoodrich Chemical company) E.bulbosa acetic acid ethyl ester extract 0.01 sodium bisulfite 0.01 ethylparaben 0.3 perfume proper amount ion Exchanged water Residue (production method) A carboxyvinyl polymer is dissolved in a small amount of ion exchanged water (phase A). Polyethylene glycol 1500 and triethanolamine are added to the remaining ion-exchanged water, dissolved by heating, and kept at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the water phase to perform preliminary emulsification, the phase A is added, and the mixture is uniformly emulsified with a homomixer. After the emulsification, the mixture is cooled to 30 ° C. while stirring well.
【0030】実施例5 乳液 (処方) マイクロクリスタリンワックス 1.0 重量% 密ロウ 2.0 ラノリン 20.0 流動パラフィン 10.0 スクワラン 5.0 ソルビタンセスキオレイン酸エステル 4.0 ポリオキシエチレン(20モル)ソルビタンモノオレイン酸エステル 1.0 プロピレングリコール 7.0 E.subaphylla アセトン抽出物 10.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し、加
熱融解して70℃に保つ(油相)。油相をかきまぜなが
らこれに水相を徐々に加え、ホモミキサーで均一に乳化
する。乳化後よくかきまぜながら30℃まで冷却する。Example 5 Emulsion (Formulation) Microcrystalline wax 1.0% by weight Beeswax 2.0 Lanolin 20.0 Liquid paraffin 10.0 Squalane 5.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) ) Sorbitan monooleate 1.0 Propylene glycol 7.0 E. subaphylla acetone extract 10.0 Sodium hydrogen sulfite 0.01 Ethylparaben 0.3 Perfume proper amount Ion-exchanged water Residue (production method) Propylene glycol is added to ion-exchanged water In addition,
Heat and maintain at 70 ° C. (aqueous phase). The other components are mixed, heated and melted and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase is gradually added thereto, and the mixture is uniformly emulsified with a homomixer. After emulsification, cool to 30 ° C with good stirring.
【0031】実施例6 ゼリー (処方) 95%エチルアルコール 10.0 重量% ジプロピレングリコール 15.0 ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0 カルボキシビニルポリマー 1.0 (商品名:カーボポール940,B.F.Goodrich Chemical company) 苛性ソーダ 0.15 L−アルギニン 0.1 ホンコン50%エタノール水溶液抽出物 7.0 2-ヒドロキシ-4-メトキシベンゾフェノンスルホン酸ナトリウム 0.05 エチレンジアミンテトラアセテート・3ナトリウム・2水 0.05 メチルパラベン 0.2 香料 適量 イオン交換水 残余 (製法)イオン交換水にカーボポール940を均一に溶
解し、一方、95%エタノールにホンコン50%エタノ
ール水溶液抽出物、ポリオキシエチレン(50モル)オ
レイルアルコールエーテルを溶解し、水相に添加する。
次いで、その他の成分を加えたのち苛性ソーダ、L−ア
ルギニンで中和させ増粘する。Example 6 Jelly (formulation) 95% ethyl alcohol 10.0% by weight dipropylene glycol 15.0 polyoxyethylene (50 mol) oleyl alcohol ether 2.0 carboxyvinyl polymer 1.0 (trade name: Carbopol) 940, BFGoodrich Chemical company) Caustic soda 0.15 L-Arginine 0.1 Hong Kong 50% ethanol aqueous solution extract 7.0 2-Hydroxy-4-methoxybenzophenone sodium sulfonate 0.05 Ethylenediaminetetraacetate ・ 3 sodium ・ 2 water 0 .05 Methylparaben 0.2 Fragrance Suitable amount Ion-exchanged water Residual (production method) Carbopol 940 was uniformly dissolved in ion-exchanged water, while 95% ethanol was extracted with a 50% ethanol solution in Hong Kong and polyoxyethylene (50 mol) oleyl. alcohol Dissolve the ether and add to the aqueous phase.
Next, after adding other components, the mixture is neutralized with caustic soda and L-arginine to increase the viscosity.
【0032】実施例7 美容液 (処方) (A相) エチルアルコール(95%) 10.0 重量% ポリオキシエチレン(20モル)オクチルドデカノール 1.0 パントテニールエチルエーテル 0.1 E.bulbosa メタノール抽出物 1.5 メチルパラベン 0.15 (B相) 水酸化カリウム 0.1 (C相) グリセリン 5.0 ジプロピレングリコール 10.0 亜硫酸水素ナトリウム 0.03 カルボキシビニルポリマー 0.2 (商品名:カーボポール940,B.F.Goodrich Chemical company) 精製水 残余 (製法)A相、C相をそれぞれ均一に溶解し、C相にA
相を加えて可溶化する。次いでB相を加えたのち充填を
行う。Example 7 Serum (formulation) (Phase A) Ethyl alcohol (95%) 10.0% by weight Polyoxyethylene (20 mol) Octyldodecanol 1.0 Pantothenyl ethyl ether 0.1 E.bulbosa methanol Extract 1.5 Methylparaben 0.15 (Phase B) Potassium hydroxide 0.1 (Phase C) Glycerin 5.0 Dipropylene glycol 10.0 Sodium bisulfite 0.03 Carboxyvinyl polymer 0.2 (trade name: Carbo Pole 940, BFGoodrich Chemical company) Purified water Residue (production method) Phases A and C are uniformly dissolved, and A is added to phase C
Add phases and solubilize. Next, after adding the phase B, filling is performed.
【0033】実施例8 パック (処方) (A相) ジプロピレングリコール 5.0 重量% ポリオキシエチレン(60モル)硬化ヒマシ油 5.0 (B相) E.subaphyllaメタノール抽出物 0.01 オリーブ油 5.0 酢酸トコフェロール 0.2 エチルパラベン 0.2 香料 0.2 (C相) 亜硫酸水素ナトリウム 0.03 ポリビニルアルコール 13.0 (ケン化度90、重合度2,000) エタノール 7.0 精製水 残余 (製法)A相、B相、C相をそれぞれ均一に溶解し、A
相にB相を加えて可溶化する。次いでこれをC相に加え
たのち充填を行う。Example 8 Pack (formulation) (Phase A) 5.0% by weight dipropylene glycol Polyoxyethylene (60 mol) hydrogenated castor oil 5.0 (Phase B) E. subaphylla methanol extract 0.01 Olive oil 5 0.0 Tocopherol acetate 0.2 Ethylparaben 0.2 Perfume 0.2 (Phase C) Sodium hydrogen sulfite 0.03 Polyvinyl alcohol 13.0 (Saponification degree 90, degree of polymerization 2,000) Ethanol 7.0 Purified water Residue (Manufacturing method) Phase A, phase B, and phase C are uniformly dissolved,
Add phase B to phase and solubilize. Next, this is added to the C phase and then filled.
【0034】実施例9 固形ファンデーション (処方) タルク 43.1 重量% カオリン 15.0 セリサイト 10.0 亜鉛華 7.0 二酸化チタン 3.8 黄色酸化鉄 2.9 黒色酸化鉄 0.2 スクワラン 8.0 イソステアリン酸 4.0 モノオレイン酸POEソルビタン 3.0 オクタン酸イソセチル 2.0 ホンコンエタノール抽出物 1.0 防腐剤 適量 香料 適量 (製法)タルク〜黒色酸化鉄の粉末成分をブレンダーで
十分混合し、これにスクワラン〜オクタン酸イソセチル
の油性成分、ホンコンエタノール抽出物、防腐剤、香料
を加え良く混練した後、容器に充填、成型する。Example 9 Solid foundation (formulation) Talc 43.1% by weight Kaolin 15.0 Sericite 10.0 Zinc white 7.0 Titanium dioxide 3.8 Yellow iron oxide 2.9 Black iron oxide 0.2 Squalane 8 0.0 isostearic acid 4.0 POE sorbitan monooleate 3.0 isocetyl octoate 2.0 Hong Kong ethanol extract 1.0 preservative appropriate amount perfume appropriate amount (manufacturing method) Talc to black iron oxide powder components are thoroughly mixed with a blender. Then, an oily component of squalane to isocetyl octoate, a Hong Kong ethanol extract, an antiseptic and a fragrance are added, and the mixture is well kneaded and then filled into a container and molded.
【0035】実施例10 乳化型ファンデーション(ク
リームタイプ) (処方) (粉体部) 二酸化チタン 10.3 重量% セリサイト 5.4 カオリン 3.0 黄色酸化鉄 0.8 ベンガラ 0.3 黒色酸化鉄 0.2 (油相) デカメチルシクロペンタシロキサン 11.5 流動パラフィン 4.5 ポリオキシエチレン変性ジメチルポリシロキサン 4.0 (水相) 精製水 50.0 1,3−ブチレングルコール 4.5 E.bulbosa エタノール抽出物 1.5 ソルビタンセスキオレイン酸エステル 3.0 防腐剤 適量 香料 適量 (製法)水相を加熱攪拌後、十分に混合粉砕した粉体部
を添加してホモミキサー処理する。更に加熱混合した油
相を加えてホモミキサー処理した後、攪拌しながら香料
を添加して室温まで冷却する。Example 10 Emulsion type foundation (cream type) (Formulation) (Powder part) Titanium dioxide 10.3% by weight Sericite 5.4 Kaolin 3.0 Yellow iron oxide 0.8 Bengala 0.3 Black iron oxide 0.2 (oil phase) decamethylcyclopentasiloxane 11.5 liquid paraffin 4.5 polyoxyethylene-modified dimethylpolysiloxane 4.0 (water phase) purified water 50.0 1,3-butylene glycol 4.5 E .bulbosa ethanol extract 1.5 sorbitan sesquioleate ester 3.0 preservative proper amount perfume proper amount (manufacturing method) After the water phase is heated and stirred, the powder portion thoroughly mixed and pulverized is added and treated with a homomixer. Further, the oil phase mixed by heating is added, and the mixture is treated with a homomixer. Then, a fragrance is added with stirring, and the mixture is cooled to room temperature.
【0036】実施例11 クリーム (処方) ステアリン酸 5.0 重量% ステアリルアルコール 4.0 イソプロピルミリステート 18.0 グリセリンモノステアリン酸エステル 3.0 プロピレングリコール 10.0 Iris pallida メタノール抽出物 0.01 苛性カリ 0.2 亜硫酸水素ナトリウム 0.01 防腐剤 適量 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールとIris p
allidaメタノール抽出物と苛性カリを加え溶解し、加熱
して70℃に保つ(水相)。他の成分を混合し加熱融解
して70℃に保つ(油相)。水相に油相を徐々に加え、
全部加え終わってからしばらくその温度に保ち反応を起
こさせる。その後、ホモミキサーで均一に乳化し、よく
かきまぜながら30℃まで冷却する。Example 11 Cream (Formulation) Stearic acid 5.0% by weight Stearyl alcohol 4.0 Isopropyl myristate 18.0 Glycerin monostearate 3.0 Propylene glycol 10.0 Iris pallida Methanol extract 0.01 Caustic potash 0.2 Sodium bisulfite 0.01 Preservative Suitable amount Perfume Suitable amount Ion-exchanged water Residual (production method) Ion-exchanged water with propylene glycol and Iris p
Add allida methanol extract and potassium hydroxide to dissolve and heat to maintain at 70 ° C (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). Add the oil phase gradually to the water phase,
After all the ingredients have been added, the temperature is maintained for a while to cause a reaction. Then, it is uniformly emulsified with a homomixer and cooled to 30 ° C. with thorough stirring.
【0037】実施例12 クリーム (処方) ステアリン酸 2.0 重量% ステアリルアルコール 7.0 水添ラノリン 2.0 スクワラン 5.0 2−オクチルドデシルアルコール 6.0 ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0 グリセリンモノステアリン酸エステル 2.0 プロピレングリコール 5.0 Iris florentina エタノール抽出物 0.05 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し加熱
融解して70℃に保つ(油相)。水相に油相を加え予備
乳化を行い、ホモミキサーで均一に乳化した後、よくか
きまぜながら30℃まで冷却する。Example 12 Cream (formulation) Stearic acid 2.0% by weight Stearyl alcohol 7.0 Hydrogenated lanolin 2.0 Squalane 5.0 2-Octyldodecyl alcohol 6.0 Polyoxyethylene (25 mol) cetyl alcohol ether 3.0 Glycerin monostearate 2.0 Propylene glycol 5.0 Iris florentina Ethanol extract 0.05 Sodium bisulfite 0.03 Ethylparaben 0.3 Fragrance Ion-exchanged water Residual (production method) Propylene glycol on ion-exchanged water And add
Heat and maintain at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the aqueous phase to carry out preliminary emulsification, and the mixture is uniformly emulsified with a homomixer and then cooled to 30 ° C. with thorough stirring.
【0038】実施例13 クリーム (処方) 固形パラフィン 5.0 重量% ミツロウ 10.0 ワセリン 15.0 流動パラフィン 41.0 グリセリンモノステアリン酸エステル 2.0 ポリオキシエチレン(20モル)ソルビタンモノラウリン酸エステル 2.0 石けん粉末 0.1 硼砂 0.2 Iris pallida アセトン抽出物 0.05 Iris florentina エタノール抽出物 0.05 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水に石けん粉末と硼砂を加え、加熱
溶解して70℃に保つ(水相)。他の成分を混合し加熱
融解して70℃に保つ(油相)。水相に油相をかきまぜ
ながら徐々に加え反応を行う。反応終了後、ホモミキサ
ーで均一に乳化し、乳化後よくかきまぜながら30℃ま
で冷却する。Example 13 Cream (formulation) Solid paraffin 5.0% by weight Beeswax 10.0 Vaseline 15.0 Liquid paraffin 41.0 Glycerin monostearate 2.0 Polyoxyethylene (20 mol) sorbitan monolaurate 2 .0 soap powder 0.1 borax 0.2 Iris pallida acetone extract 0.05 Iris florentina ethanol extract 0.05 sodium bisulfite 0.03 ethylparaben 0.3 perfume proper amount ion-exchanged water residual (production method) ion-exchanged water Soap powder and borax are added to the mixture, heated and melted and kept at 70 ° C (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is gradually added to the aqueous phase while stirring to carry out the reaction. After the reaction is completed, the mixture is uniformly emulsified with a homomixer, and after emulsification, the mixture is cooled to 30 ° C. with thorough stirring.
【0039】実施例14 乳液 (処方) ステアリン酸 2.5 重量% セチルアルコール 1.5 ワセリン 5.0 流動パラフィン 10.0 ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0 ポリエチレングリコール1500 3.0 トリエタノールアミン 1.0 カルボキシビニルポリマー 0.05 (商品名:カーボポール941,B.F.Goodrich Chemical company) Iris pallida 酢酸エチルエステル抽出物 0.01 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)少量のイオン交換水にカルボキシビニルポリマ
ーを溶解する(A相)。残りのイオン交換水にポリエチ
レングリコール1500とトリエタノールアミンを加
え、加熱溶解して70℃に保つ(水相)。他の成分を混
合し加熱融解して70℃に保つ(油相)。水相に油相を
加え予備乳化を行い、A相を加えホモミキサーで均一乳
化し、乳化後よくかきまぜながら30℃まで冷却する。Example 14 Emulsion (formulation) Stearic acid 2.5% by weight Cetyl alcohol 1.5 Vaseline 5.0 Liquid paraffin 10.0 Polyoxyethylene (10 mol) monooleate 2.0 Polyethylene glycol 1500 3. 0 Triethanolamine 1.0 Carboxyvinyl polymer 0.05 (Brand name: Carbopol 941, BFGoodrich Chemical company) Iris pallida Acetic acid ethyl ester extract 0.01 Sodium hydrogen sulfite 0.01 Ethyl paraben 0.3 Perfume Ion exchange Water Residue (Production Method) A carboxyvinyl polymer is dissolved in a small amount of ion-exchanged water (phase A). Polyethylene glycol 1500 and triethanolamine are added to the remaining ion-exchanged water, dissolved by heating, and kept at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the water phase to perform preliminary emulsification, the phase A is added, and the mixture is uniformly emulsified with a homomixer. After the emulsification, the mixture is cooled to 30 ° C. while stirring well.
【0040】実施例15 乳液 (処方) マイクロクリスタリンワックス 1.0 重量% 密ロウ 2.0 ラノリン 20.0 流動パラフィン 10.0 スクワラン 5.0 ソルビタンセスキオレイン酸エステル 4.0 ポリオキシエチレン(20モル)ソルビタンモノオレイン酸エステル 1.0 プロピレングリコール 7.0 Iris florentina アセトン抽出物 10.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し、加
熱融解して70℃に保つ(油相)。油相をかきまぜなが
らこれに水相を徐々に加え、ホモミキサーで均一に乳化
する。乳化後よくかきまぜながら30℃まで冷却する。Example 15 Emulsion (formulation) Microcrystalline wax 1.0 wt% Beeswax 2.0 Lanolin 20.0 Liquid paraffin 10.0 Squalane 5.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) ) Sorbitan monooleate 1.0 Propylene glycol 7.0 Iris florentina Acetone extract 10.0 Sodium hydrogen sulfite 0.01 Ethyl paraben 0.3 Fragrance suitable amount Ion-exchanged water Residual (production method) Add propylene glycol to ion-exchanged water ,
Heat and maintain at 70 ° C. (aqueous phase). The other components are mixed, heated and melted and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase is gradually added thereto, and the mixture is uniformly emulsified with a homomixer. After emulsification, cool to 30 ° C with good stirring.
【0041】実施例16 ゼリー (処方) 95%エチルアルコール 10.0 重量% ジプロピレングリコール 15.0 ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0 カルボキシビニルポリマー 1.0 (商品名:カーボポール940,B.F.Goodrich Chemical company) 苛性ソーダ 0.15 L−アルギニン 0.1 Iris pallida50%エタノール水溶液抽出物 7.0 2-ヒドロキシ-4-メトキシベンゾフェノンスルホン酸ナトリウム 0.05 エチレンジアミンテトラアセテート・3ナトリウム・2水 0.05 メチルパラベン 0.2 香料 適量 イオン交換水 残余 (製法)イオン交換水にカーボポール940を均一に溶
解し、一方、95%エタノールにIris pallida50%エ
タノール水溶液抽出物、ポリオキシエチレン(50モ
ル)オレイルアルコールエーテルを溶解し、水相に添加
する。次いで、その他の成分を加えたのち苛性ソーダ、
L−アルギニンで中和させ増粘する。Example 16 Jelly (formulation) 95% ethyl alcohol 10.0% by weight dipropylene glycol 15.0 polyoxyethylene (50 mol) oleyl alcohol ether 2.0 carboxyvinyl polymer 1.0 (trade name: Carbopol) 940, BFGoodrich Chemical company) Caustic soda 0.15 L-arginine 0.1 Iris pallida 50% ethanol aqueous solution extract 7.0 2-Hydroxy-4-methoxybenzophenone sulfonate sodium 0.05 Ethylenediaminetetraacetate ・ 3 sodium ・ dihydrate 0 .05 Methylparaben 0.2 Fragrance Appropriate amount Ion-exchanged water Residual (production method) Carbopol 940 is uniformly dissolved in ion-exchanged water, while Iris pallida 50% ethanol aqueous solution extract and polyoxyethylene (50 mol) oleyl in 95% ethanol Arcor Ruether is dissolved and added to the aqueous phase. Next, after adding other ingredients, caustic soda,
Thicken by neutralizing with L-arginine.
【0042】[0042]
【発明の効果】以上説明したように、本発明の美白用皮
膚外用剤は、メラニン生成抑制作用およびチロシナーゼ
活性阻害作用を有しており、日焼け後の色素沈着・しみ
・そばかす・肝斑等の淡色化、美白に優れた効果を有す
ると共に、安全性にも優れた美白用皮膚外用剤である。Industrial Applicability As described above, the whitening skin external preparation of the present invention has a melanin production inhibitory action and a tyrosinase activity inhibitory action, and is effective in treating pigmentation, stains, freckles, melasma, etc. after sunburn. It is an external preparation for whitening skin, which has excellent effects on lightening and whitening, and is also excellent in safety.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 芝田 由記 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第一リサーチセンター内 (72)発明者 長沼 雅子 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第一リサーチセンター内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Yuki Shibata 1050 Shinba-cho, Kohoku-ku, Yokohama-shi, Kanagawa Inside Shiseido Daiichi Research Center, Inc. (72) Inventor Masako Naganuma 1050 Shinba-cho, Kohoku-ku, Yokohama-shi, Kanagawa Shiseido Daiichi Research Center Co., Ltd.
Claims (4)
配合することを特徴とする美白用皮膚外用剤。1. An external preparation for whitening skin, comprising a plant extract of the family Iridaceae.
(Eleutherin)の植物抽出物である請求項1記載の美白
用皮膚外用剤。2. The external preparation for whitening skin according to claim 1, wherein the plant extract of the family Iridaceae is a plant extract of the genus Eleutherin.
s)の植物抽出物である請求項1記載の美白用皮膚外用
剤。3. A plant extract of the family Iridaceae belongs to the genus Iri.
The external preparation for whitening skin according to claim 1, which is the plant extract of s).
05〜20.0重量%である請求項1〜3のいずれかに
記載の美白用皮膚外用剤。4. The blending amount of the iris family plant extract is 0.0.
The external preparation for whitening skin according to any one of claims 1 to 3, which is 05 to 20.0% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP08475096A JP3481386B2 (en) | 1995-05-17 | 1996-03-13 | Skin whitening preparation for external use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7-142680 | 1995-05-17 | ||
| JP14268095 | 1995-05-17 | ||
| JP08475096A JP3481386B2 (en) | 1995-05-17 | 1996-03-13 | Skin whitening preparation for external use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0930954A true JPH0930954A (en) | 1997-02-04 |
| JP3481386B2 JP3481386B2 (en) | 2003-12-22 |
Family
ID=30117246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP08475096A Expired - Lifetime JP3481386B2 (en) | 1995-05-17 | 1996-03-13 | Skin whitening preparation for external use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3481386B2 (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124499A (en) * | 1995-09-07 | 1997-05-13 | L'oreal Sa | Iridaceae plant extract and composition containing the same |
| FR2760191A1 (en) * | 1997-03-03 | 1998-09-04 | Oreal | ASSOCIATION OF PHENOL DERIVATIVES AND AN EXTRACT OF IRIDACEES FOR THE DEPIGMENTATION OF THE SKIN OR ITS PHANES AND COMPOSITION COMPRISING THE SAME |
| JPH11335233A (en) * | 1998-05-22 | 1999-12-07 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor and cosmetic composition |
| JP2000302667A (en) * | 1999-04-23 | 2000-10-31 | Kobe Tennenbutsu Kagaku Kk | Breast augmentation agent |
| JP2002121143A (en) * | 2000-10-13 | 2002-04-23 | Nonogawa Shoji Kk | Skin care preparation |
| JP2006124355A (en) * | 2004-11-01 | 2006-05-18 | Ichimaru Pharcos Co Ltd | Phagocytosis inhibitor |
| JP2007308516A (en) * | 2001-03-23 | 2007-11-29 | Rohto Pharmaceut Co Ltd | Integumentary composition |
| WO2010090001A1 (en) | 2009-02-09 | 2010-08-12 | 株式会社資生堂 | Skin-whitening agent, anti-aging agent, and anti-oxidant agent |
| WO2011018885A1 (en) | 2009-08-11 | 2011-02-17 | 株式会社資生堂 | Preparation for external application to skin, skin whitening agent, antioxidant agent, and anti-aging agent |
| CN103091445A (en) * | 2012-08-23 | 2013-05-08 | 广州白云华南生物科技有限公司 | Quality detection method of Eleutherine plicata Herb and extract thereof |
| JP2015030720A (en) * | 2013-08-07 | 2015-02-16 | 一丸ファルコス株式会社 | Kinesin inhibitor |
| KR102490802B1 (en) * | 2021-08-18 | 2023-01-20 | 주식회사 엑소코바이오 | New composition comprising exosomes derived from Iris as an active ingredient |
| KR20240079289A (en) * | 2022-11-28 | 2024-06-05 | 국립낙동강생물자원관 | Skin-lightening Composition Using an Extract of Iris pseudacorus |
| JP2024522137A (en) * | 2021-06-04 | 2024-06-11 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | Orris root extract, composition and method of skin application |
| JP2024532404A (en) * | 2021-08-27 | 2024-09-05 | ピーピー プロデュイ プレスティージュ エス エー | A cosmetic composition containing exosomes derived from iris bulbs as an active ingredient |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0725762A (en) * | 1993-07-14 | 1995-01-27 | Sansho Seiyaku Co Ltd | External skin preparation |
| JPH07277944A (en) * | 1994-04-11 | 1995-10-24 | Narisu Keshohin:Kk | Melanin production inhibitor |
| JPH0812559A (en) * | 1994-06-29 | 1996-01-16 | Shiseido Co Ltd | Skin external preparation |
-
1996
- 1996-03-13 JP JP08475096A patent/JP3481386B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0725762A (en) * | 1993-07-14 | 1995-01-27 | Sansho Seiyaku Co Ltd | External skin preparation |
| JPH07277944A (en) * | 1994-04-11 | 1995-10-24 | Narisu Keshohin:Kk | Melanin production inhibitor |
| JPH0812559A (en) * | 1994-06-29 | 1996-01-16 | Shiseido Co Ltd | Skin external preparation |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124499A (en) * | 1995-09-07 | 1997-05-13 | L'oreal Sa | Iridaceae plant extract and composition containing the same |
| US6471997B1 (en) * | 1995-09-07 | 2002-10-29 | Societe L'oreal S.A. | Iridaceae extract and compositions containing it |
| FR2760191A1 (en) * | 1997-03-03 | 1998-09-04 | Oreal | ASSOCIATION OF PHENOL DERIVATIVES AND AN EXTRACT OF IRIDACEES FOR THE DEPIGMENTATION OF THE SKIN OR ITS PHANES AND COMPOSITION COMPRISING THE SAME |
| WO1998038978A1 (en) * | 1997-03-03 | 1998-09-11 | L'oreal | Association of phenol derivatives with extract of iridaceae family for lightening the skin and superficial body growth and composition containing same |
| JPH11335233A (en) * | 1998-05-22 | 1999-12-07 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor and cosmetic composition |
| JP2000302667A (en) * | 1999-04-23 | 2000-10-31 | Kobe Tennenbutsu Kagaku Kk | Breast augmentation agent |
| JP2002121143A (en) * | 2000-10-13 | 2002-04-23 | Nonogawa Shoji Kk | Skin care preparation |
| JP2007308516A (en) * | 2001-03-23 | 2007-11-29 | Rohto Pharmaceut Co Ltd | Integumentary composition |
| JP2006124355A (en) * | 2004-11-01 | 2006-05-18 | Ichimaru Pharcos Co Ltd | Phagocytosis inhibitor |
| WO2010090001A1 (en) | 2009-02-09 | 2010-08-12 | 株式会社資生堂 | Skin-whitening agent, anti-aging agent, and anti-oxidant agent |
| WO2011018885A1 (en) | 2009-08-11 | 2011-02-17 | 株式会社資生堂 | Preparation for external application to skin, skin whitening agent, antioxidant agent, and anti-aging agent |
| CN103091445A (en) * | 2012-08-23 | 2013-05-08 | 广州白云华南生物科技有限公司 | Quality detection method of Eleutherine plicata Herb and extract thereof |
| JP2015030720A (en) * | 2013-08-07 | 2015-02-16 | 一丸ファルコス株式会社 | Kinesin inhibitor |
| JP2024522137A (en) * | 2021-06-04 | 2024-06-11 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | Orris root extract, composition and method of skin application |
| KR102490802B1 (en) * | 2021-08-18 | 2023-01-20 | 주식회사 엑소코바이오 | New composition comprising exosomes derived from Iris as an active ingredient |
| WO2023022414A1 (en) * | 2021-08-18 | 2023-02-23 | 주식회사 엑소코바이오 | Novel composition comprising iris-derived exosome as active ingredient |
| US12605331B2 (en) | 2021-08-18 | 2026-04-21 | Exocobio Inc. | Composition comprising iris-derived exosome as active ingredient |
| JP2024532404A (en) * | 2021-08-27 | 2024-09-05 | ピーピー プロデュイ プレスティージュ エス エー | A cosmetic composition containing exosomes derived from iris bulbs as an active ingredient |
| KR20240079289A (en) * | 2022-11-28 | 2024-06-05 | 국립낙동강생물자원관 | Skin-lightening Composition Using an Extract of Iris pseudacorus |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3481386B2 (en) | 2003-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3481386B2 (en) | Skin whitening preparation for external use | |
| JPH0930946A (en) | Beautifying and whitening dermal preparation for external use | |
| JPH11246347A (en) | Preparation for external use for skin bleaching | |
| JPH0812560A (en) | Skin external preparation | |
| JPH0812561A (en) | Beautifying and whitening skin preparation for external use | |
| JPH0812566A (en) | Inhibitor of tyrosinase activity | |
| JPH0925209A (en) | Skin preparation for external use | |
| JPH08310939A (en) | Beautifying and whitening dermal preparation for external use | |
| JPH0930945A (en) | Dermal preparation for external use | |
| JP3140357B2 (en) | Skin whitening agent | |
| JPH0930949A (en) | Beautifying and whitening dermal preparation for external use | |
| JP2000159626A (en) | Preparation for external use for skin | |
| JPH0812549A (en) | Skin external preparation | |
| JPH0812552A (en) | Skin external preparation | |
| JPH0930948A (en) | Beautifying and whitening dermal preparation for external use | |
| JPH08301758A (en) | Skin preparation for external use | |
| JPH0920635A (en) | Whitening skin preparation for external use | |
| JPH0930947A (en) | Beautifying and whitening dermal preparation for external use | |
| JPH0812557A (en) | Skin external preparation | |
| JPH0812564A (en) | Skin external preparation | |
| JPH0920636A (en) | Skin preparation for external use | |
| JPH0812550A (en) | Skin external preparation | |
| JP3354031B2 (en) | External preparation for skin | |
| JP3263246B2 (en) | External preparation for skin | |
| JPH0920634A (en) | Whitening skin preparation for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20030930 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S801 | Written request for registration of abandonment of right |
Free format text: JAPANESE INTERMEDIATE CODE: R311801 |
|
| ABAN | Cancellation of abandonment | ||
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |